Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone antibiotic presented as an oral tablet for systemic use. It treats infections caused by susceptible Gram‑positive bacteria, including MRSA and VRE, in adult patients.

GNH USA supplies Linezolid Krka as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is indicated for bacterial infections caused by susceptible Gram‑positive organisms.

- Skin and soft tissue infections: effective against MRSA and other Gram‑positive pathogens, reducing infection severity. - Community‑acquired bacterial pneumonia: treats pneumonia caused by susceptible strains, improving respiratory outcomes. - Complicated urinary tract infections: eradicates susceptible Gram‑positive bacteria, aiding resolution of infection.

Linezolid may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Diarrhea - Headache - Vomiting - Metallic taste - Insomnia

Serious or Rare Side Effects: - Thrombocytopenia - Anemia - Peripheral neuropathy - Serotonin syndrome - Lactic acidosis - Optic neuritis

When prescribing Linezolid, clinicians should consider several safety aspects.

- Renal impairment: adjust therapy based on renal function and monitor labs. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant serotonergic agents: avoid due to risk of serotonin syndrome. - Prolonged therapy: monitor blood counts for hematologic toxicity. - Hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in original container, protect from moisture and light.

Linezolid interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): may precipitate serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome. - Rifampicin: reduces linezolid plasma levels, decreasing efficacy. - Anticoagulants (warfarin): may increase bleeding risk. - Erythropoietin‑stimulating agents: may reduce effectiveness.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of bleeding. - Anticonvulsants (phenytoin): may alter linezolid levels. - Theophylline: monitor for increased toxicity. - CYP450 substrates: linezolid is a weak MAO inhibitor, monitor. - Alcohol: may enhance CNS depression.